NOVARTIS

Cosentyx Rheum - HCP resources - HCP

Prescribing information

Image

Image

Cosentyx® (secukinumab): HCP resources

Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate conventional

therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years or older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[1]

Full indication for Cosentyx can be found here.

Cosentyx Summary of Product Characteristics (SmPC) can be found here.

Explore our range of educational resources designed for you and your patients

These promotional resources are developed and funded by Novartis UK for healthcare professionals to support their education and the initiation and treatment of patients throughout their Cosentyx journey. Navigate the sections below to find educational resources for download and use by healthcare professionals only, as well as resources that you can share with your patients.

Please do not share links to this page with patients.

This section of the website is intended for HCPs only, and contains promotional material. If you wish to direct patients to the patient resources, use the link below:

pro.novartis.com/uk-en/public/medicines/rheumatology/cosentyx/patient-resources

---

- Resources for HCPs

- Video resources for HCPs

- Resources for patients

Image



Confidence to prescribe Cosentyx

PDF
[Download]
Image

Promotional material produced and funded by Novartis for UK healthcare professionals only.

Prescribing information can be found here.

1,000,000 patients treated globally and counting, across indications[8]

Cosentyx® secukinumab

Proven efficacy in skin and joints with Cosentyx® (secukinumab)[1–7]

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Indications:

Treatment of: **moderate to severe plaque psoriasis** in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; **active psoriatic arthritis** in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; **active ankylosing spondylitis** in adults who have responded inadequately to conventional therapy; **active non-radiographic axial spondyloarthritis** with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; **active enthesitis-related arthritis and juvenile psoriatic arthritis** in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; **active moderate to severe hidradenitis suppurativa (acne inversa)** in adults with an inadequate response to conventional systemic HS therapy.[9]

Please refer to the Cosentyx Summary of Product Characteristics (SmPC) for further information about the clinical indications.[9]

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for dosing in special populations.[9]

UK | February 2025 | FA-11323632

NOVARTIS

Efficacy with Cosentyx

PDF
Download

- Resources for HCPs

- Video resources for HCPs

- Resources for patients

Video

5 mins 56 secs

SensoReady® 150 mg injection video

Video - 15 Jul 2024

5 mins 56 secs

SensoReady® 150 mg injection video

A short video showing you how to prepare and inject Cosentyx with the SensoReady® pen.

See more details

Hide details

Video

UnoReady® 300 mg injection video

Video - 18 Feb 2025

UnoReady® 300 mg injection video

A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen.

See more details

Hide details

- Resources for HCPs

- Video resources for HCPs

- Resources for patients

Image

PsA patient leaflet

PDF
Download
Image

AS patient leaflet

PDF
Download
Image

ERA patient leaflet

PDF
Download
Image

JPsA patient leaflet

PDF
Download
Image

UnoReady 300 mg alert leaflet

PDF
Download

Image

Digital dosing schedule – PsA

PDF
[Download]
Image

Digital dosing schedule – axSpA

PDF
Download
Image



Digital dosing schedule – PsA Q2W

PDF
Download

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information and administration, including dosing in special populations, before prescribing.[1] Cosentyx has not been studied in patients with renal impairment or hepatic impairment. No dose recommendations can be made.

Therapeutic Indications[1]

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to

severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[1]

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA; enthesitis-related arthritis; GB, Great Britain; HCP, healthcare professional; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NI, Northern Ireland; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics.

Reference

1. Cosentyx® (secukinumab) Summary of Product Characteristics

UK | March 2025 | FA-11357098-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:
https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/resources